News
09-20-2010, 06:51 AM
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
More... (http://www.news-medical.net/news/20100920/Celldex-commences-CDX-011-Phase-2b-trial-in-advanced-breast-cancer-patients-expressing-GPNMB.aspx)
More... (http://www.news-medical.net/news/20100920/Celldex-commences-CDX-011-Phase-2b-trial-in-advanced-breast-cancer-patients-expressing-GPNMB.aspx)